From: Clinical significance of clusterin expression in pancreatic adenocarcinoma
Parameter | Number of cases (%) | Clusterin expression | Survival analysis | ||
---|---|---|---|---|---|
 |  | Clusterin-positive cases (%) | P value | Median survival (months) | P value |
Overall | 52 (100.0) | 17 (32.7) | Â | 14.9 | Â |
Age | Â | Â | 0.780 | Â | 0.029 |
 ≥65 years | 35 (67.3) | 11 (31.4) |  | 10.4 |  |
  < 65 years | 17 (32.7) | 6 (35.3) |  | 38.7 |  |
Sex | Â | Â | 0.747 | Â | 0.792 |
 Male | 37 (71.2) | 13 (35.1) |  | 15.0 |  |
 Female | 15 (28.8) | 4 (26.7) |  | 10.4 |  |
Tumor size | Â | Â | 0.241 | Â | 0.075 |
 ≤2 cm | 9 (17.3) | 1 (11.1) |  | 35.4 |  |
  > 2 cm | 43 (82.7) | 16 (37.2) |  | 14.7 |  |
Location | Â | Â | 0.413 | Â | 0.648 |
 Head | 44 (84.6) | 13 (29.5) |  | 15.0 |  |
 Body/tail | 8 (15.4) | 4 (50.0) |  | 9.9 |  |
Pathologic grade | Â | Â | 0.711 | Â | 0.010 |
 Well/moderately differentiated | 42 (80.8) | 13 (31.0) |  | 15.9 |  |
 Poorly differentiated/anaplastic | 10 (19.2) | 4 (40.0) |  | 3.1 |  |
Perineural invasion | Â | Â | 0.042 | Â | 0.414 |
 No | 8 (15.4) | 0 (0.0) |  | 18.5 |  |
 Yes | 44 (84.6) | 17 (32.7) |  | 11.5 |  |
Lymphovascular invasion | Â | Â | 0.330 | Â | 0.055 |
 No | 15 (28.8) | 3 (20.0) |  | 39.6 |  |
 Yes | 37 (71.2) | 14 (37.8) |  | 8.9 |  |
Preoperative CEA (ng/ml) | Â | Â | 0.048 | Â | 0.787 |
 ≤5 | 32 (69.6) | 8 (25.0) |  | 15.0 |  |
  > 5 | 14 (30.4) | 8 (57.1) |  | 14.7 |  |
Preoperative CA19-9 (U/ml) | Â | Â | 1.000 | Â | 0.640 |
 ≤37 | 15 (33.3) | 5 (33.3) |  | 15.9 |  |
  > 37 | 30 (66.7) | 10 (33.3) |  | 16.5 |  |
Lymph node metastasis | Â | Â | 0.006 | Â | 0.002 |
 No | 16 (31.4) | 1 (6.3) |  | 39.7 |  |
 Yes | 35 (68.6) | 16 (45.7) |  | 9.9 |  |
Clusterin expression |  |  | – |  | 0.312 |
 Negative | 35 (67.3) | – |  | 15.0 |  |
 Positive | 17 (32.7) | – |  | 14.9 |  |